Table V.
Adverse events
| Adverse event* | Any grade | Grade 3 or 4 (%) (n = 99) | ||
|---|---|---|---|---|
| All (%) (n = 99) | Among responders (%) (n = 70) | Among non-responders (%) (n = 29) | ||
| Lymphopenia | 74 (74.7) | 53 (75.7) | 21 (72.4) | 14 (14.1) |
| Anemia | 64 (64.6) | 43 (61.4) | 21 (72.4) | 5 (5.1) |
| Neutropenia | 61 (61.6) | 47 (67.1) | 14 (48.3) | 10 (10.1) |
| Fatigue | 50 (50.5) | 39 (55.7) | 11 (37.9) | 7 (7.1) |
| Thrombocytopenia | 45 (45.5) | 31 (44.3) | 14 (48.3) | 5 (5.1) |
| Nausea | 41 (41.4) | 29 (41.4) | 12 (41.4) | 2 (2) |
| Diarrhea | 27 (27.3) | 19 (27.1) | 8 (27.6) | 1 (1) |
| Elevated ALT | 25 (25.2) | 16 (22.9) | 9 (31) | 1 (1) |
| Peripheral edema | 22 (22.2) | 16 (22.9) | 6 (20.7) | 0 (0) |
| Elevated AST | 21 (21.2) | 14 (20) | 7 (24.1) | 0 (0) |
| Rash | 17 (17.2) | 12 (17.1) | 5 (17.2) | 0 (0) |
| Alopecia | 15 (15.1) | 13 (18.6) | 2 (6.9) | NA |
*
Adverse events observed in 15% or more of the patients, and grade 3 or 4 adverse events observed in 2% or more of the patients are listed.
ALT – alanine aminotransferase, AST – aspartate aminotransferase.